Compare Stocks

→ Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATE Antibe Therapeutics	C$0.30	C$0.51	C$0.15 ▼ C$1.23	C$15.54M	0.12	135,475 shs	N/A
BTX Brooklyn ImmunoTherapeutics	$1.74 -11.2%	$2.15	$0.17 ▼ $10.10	$102.36M	4.61	515,543 shs	11,932 shs
OKYO OKYO Pharma	$1.41 +0.7%	$1.44	$0.92 ▼ $3.25	$40.37M	0.04	26,610 shs	50,202 shs
SBTX Silverback Therapeutics	$8.26 -2.8%	$8.80	$2.80 ▼ $8.97	$297.84M	0.6	337,931 shs	334,673 shs

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATE Antibe Therapeutics	0.00%	0.00%	-31.40%	-67.58%	-45.37%
BTX Brooklyn ImmunoTherapeutics	-11.22%	-19.07%	-57.58%	-1.14%	-46.14%
OKYO OKYO Pharma	-1.40%	0.00%	-3.42%	-10.76%	+10.16%
SBTX Silverback Therapeutics	+0.61%	-8.83%	-9.53%	+29.47%	+26.49%

Will this $2 AI stock double overnight? (Ad)

It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!

Click here to learn more >>>

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATE Antibe Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BTX Brooklyn ImmunoTherapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	1.668 of 5 stars	3.5	3.0	0.0	0.0	0.6	1.7	0.6
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATE Antibe Therapeutics	2.00	Hold	N/A	N/A
BTX Brooklyn ImmunoTherapeutics	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	3.00	Buy	$7.00	396.45% Upside
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest OKYO, BTX, SBTX, and ATE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
3/22/2024	OKYO OKYO Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$6.00 ➝ $7.00
3/4/2024	ATE Antibe Therapeutics	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATE Antibe Therapeutics	C$9.71M	1.60	C$0.48 per share	0.61	C$0.49 per share	0.60
BTX Brooklyn ImmunoTherapeutics	N/A	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	($0.08) per share	N/A
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	$7.41 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATE Antibe Therapeutics	-C$18.24M	-C$0.35	N/A	∞	N/A	N/A	-52.72%	-19.13%	7/4/2024 (Estimated)
BTX Brooklyn ImmunoTherapeutics	N/A	-$2.27	N/A	∞	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	-$13.27M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/20/2024 (Estimated)
SBTX Silverback Therapeutics	-$89.48M	-$2.42	N/A	∞	N/A	N/A	-29.62%	-28.20%	N/A

Latest OKYO, BTX, SBTX, and ATE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/14/2024	Q3 2024	ATE Antibe Therapeutics	-C$0.12	-C$0.08	+C$0.04	-C$0.08	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATE Antibe Therapeutics	C$0.05	16.95%	N/A	N/A	N/A
BTX Brooklyn ImmunoTherapeutics	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	N/A
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATE Antibe Therapeutics	0.29	10.06	9.58
BTX Brooklyn ImmunoTherapeutics	N/A	N/A	N/A
OKYO OKYO Pharma	N/A	N/A	N/A
SBTX Silverback Therapeutics	N/A	67.87	67.87

Ownership

Institutional Ownership

Company	Institutional Ownership
ATE Antibe Therapeutics	N/A
BTX Brooklyn ImmunoTherapeutics	26.00%
OKYO OKYO Pharma	2.97%
SBTX Silverback Therapeutics	74.89%

Insider Ownership

Company	Insider Ownership
ATE Antibe Therapeutics	7.94%
BTX Brooklyn ImmunoTherapeutics	20.50%
OKYO OKYO Pharma	40.46%
SBTX Silverback Therapeutics	34.40%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ATE Antibe Therapeutics	11	52.67 million	N/A	Not Optionable
BTX Brooklyn ImmunoTherapeutics	N/A	58.83 million	N/A	No Data
OKYO OKYO Pharma	8	28.83 million	17.17 million	Not Optionable
SBTX Silverback Therapeutics	83	36.06 million	23.65 million	Not Optionable

OKYO, BTX, SBTX, and ATE Headlines

Source	Headline
	Silverback Therapeutics (NASDAQ:SBTX) Trading Down 2.8% americanbankingnews.com - April 25 at 1:48 AM
	Silverback Therapeutics (NASDAQ:SBTX) Trading Down 2% marketbeat.com - April 3 at 2:15 AM
	ARS Pharmaceuticals Inc (SPRY) uk.investing.com - May 11 at 1:32 PM
	Wild Isles wwf.org.uk - March 12 at 9:31 AM
	A look back at RNA Therapeutics – day one pharmaphorum.com - February 24 at 12:35 AM
	SPRY ARS Pharmaceuticals, Inc. seekingalpha.com - January 24 at 8:04 PM
	ARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After Merger 247wallst.com - November 22 at 6:29 AM
	Dr. Sarina Tanimoto Discloses Position in SBTX / Silverback Therapeutics nasdaq.com - November 18 at 8:19 PM
	ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis finance.yahoo.com - November 10 at 6:41 PM
	ARS Pharmaceuticals Closes Merger with Silverback Therapeutics finance.yahoo.com - November 8 at 5:59 PM
	Silverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic Reactions markets.businessinsider.com - October 28 at 8:15 AM
	FDA accepts ARS Pharma’s NDA for Neffy thepharmaletter.com - October 24 at 10:29 AM
	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERI kentuckytoday.com - October 23 at 7:22 PM
	Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis finance.yahoo.com - October 21 at 7:59 AM
	Is Silverback Therapeutics Inc (SBTX) Stock a Good Investment? aaii.com - October 19 at 11:52 AM
	SHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger – RFP, SBTX, AAWW, COWN bakersfield.com - October 12 at 11:07 PM
	INVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBT markets.businessinsider.com - September 17 at 5:10 AM
	SBTX Silverback Therapeutics, Inc. seekingalpha.com - September 15 at 10:58 PM
	SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBT markets.businessinsider.com - September 6 at 11:53 AM
	SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZY markets.businessinsider.com - August 23 at 6:32 PM
	SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates VIVO, HNGR, SBTX apnews.com - August 17 at 12:02 PM
	SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates IEA, BBQ, SBTX apnews.com - August 11 at 1:33 AM
	SHAREHOLDER ALERT: Weiss Law Reminds SBTX, LJPC, CNVY, and DRE Shareholders About Its Ongoing Investigations morningstar.com - July 30 at 7:00 AM
	INVESTIGATION ALERT: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZY apnews.com - July 28 at 2:21 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Antibe Therapeutics

TSE:ATE

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Brooklyn ImmunoTherapeutics

NYSE:BTX

Eterna Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B. The company is headquartered in San Diego, CA.

OKYO Pharma

NASDAQ:OKYO

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Silverback Therapeutics

NASDAQ:SBTX

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial